Home › Funds › ARS Investment Partners, LLC › REGN
ARS Investment Partners, LLC position in REGN
REGENERON PHARMACEUTICALS · Health Care
ARS Investment Partners, LLC reported holding 44,514 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$33.8M, representing 1.52% of its reported portfolio and ranking #19 among its reported holdings. ARS Investment Partners, LLC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ARS Investment Partners, LLC's REGN position evolved
ARS Investment Partners, LLC first disclosed a stake in REGN in Q1 2024 at 12,006 shares (US$11.6M). The position peaked in Q1 2026 at 45,270 shares, worth US$35.0M. Across 11 filings, ARS Investment Partners, LLC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 44,514 shares valued at US$33.8M — a reduction of -970 shares quarter over quarter.. Notable position changes include a 46% trim in Q4 2024 (shares fell 11% over the following quarter), a 222% increase in Q2 2025 (shares rose 8% over the following quarter), a 38% increase in Q3 2025 (shares rose 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 12.01K | $11.56M | New |
| Q2 2024 | 11.88K | $12.48M | Reduce |
| Q3 2024 | 12.02K | $12.64M | Add |
| Q4 2024 | 6.48K | $4.62M | Reduce |
| Q1 2025 | 6.48K | $4.61M | Hold |
| Q2 2025 | 20.86K | $10.95M | Add |
| Q3 2025 | 28.77K | $16.18M | Add |
| Q4 2025 | 35.45K | $27.36M | Add |
| Q1 2026 | 45.27K | $34.98M | Add |
| Q2 2026 | 45.48K | $28.36M | Hold |
| Q3 2026 | 44.51K | $33.75M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- Franklin Resources 2.95M sh · $2.75B · Q3 2026
- Nuveen, LLC 1.96M sh · $1.48B · Q3 2026
- LOOMIS SAYLES & CO L P 1.72M sh · $1.30B · Q3 2026
More on ARS Investment Partners, LLC
FAQ
How long has ARS Investment Partners, LLC held REGN?
ARS Investment Partners, LLC has disclosed REGN holdings in 11 of the last 11 reported quarters, going back to Q1 2024.
What is ARS Investment Partners, LLC's current position in REGN?
As of Q3 2026, ARS Investment Partners, LLC holds 44.51K shares of REGN (REGENERON PHARMACEUTICALS), valued at $33.75M, representing 1.52% of its reported portfolio and ranking #19.
Has ARS Investment Partners, LLC been buying or selling REGN?
In the latest 13F filing (Q3 2026), ARS Investment Partners, LLC reduced its position in REGN. The position peaked in Q1 2026 at 45.27K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.